UniSuper Management Pty Ltd Acquires 20,862 Shares of Moderna, Inc. (NASDAQ:MRNA)

UniSuper Management Pty Ltd increased its stake in shares of Moderna, Inc. (NASDAQ:MRNA - Free Report) by 69.3% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 50,953 shares of the company's stock after buying an additional 20,862 shares during the quarter. UniSuper Management Pty Ltd's holdings in Moderna were worth $2,119,000 at the end of the most recent reporting period.

A number of other hedge funds also recently modified their holdings of MRNA. Cerity Partners LLC raised its holdings in shares of Moderna by 7.0% during the 3rd quarter. Cerity Partners LLC now owns 13,769 shares of the company's stock worth $920,000 after buying an additional 900 shares in the last quarter. Fisher Asset Management LLC bought a new position in shares of Moderna in the 3rd quarter valued at $419,000. Quantbot Technologies LP bought a new stake in Moderna during the 3rd quarter worth $150,000. Townsquare Capital LLC raised its position in Moderna by 42.7% in the third quarter. Townsquare Capital LLC now owns 5,288 shares of the company's stock valued at $353,000 after purchasing an additional 1,583 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank boosted its position in Moderna by 17.6% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 157,774 shares of the company's stock worth $10,544,000 after buying an additional 23,631 shares during the period. Institutional investors own 75.33% of the company's stock.

Moderna Price Performance

NASDAQ MRNA traded up $0.56 during trading hours on Wednesday, hitting $27.72. The company's stock had a trading volume of 11,792,223 shares, compared to its average volume of 6,926,228. Moderna, Inc. has a 12 month low of $26.32 and a 12 month high of $170.47. The company's 50 day simple moving average is $34.43 and its two-hundred day simple moving average is $43.55. The company has a market cap of $10.72 billion, a P/E ratio of -2.99 and a beta of 1.86.

Remove Ads

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on MRNA shares. UBS Group reduced their price target on shares of Moderna from $96.00 to $78.00 and set a "buy" rating for the company in a report on Wednesday, February 19th. Morgan Stanley reduced their price objective on Moderna from $70.00 to $38.00 and set an "equal weight" rating for the company in a research note on Wednesday, January 15th. Royal Bank of Canada reissued a "sector perform" rating and issued a $40.00 target price on shares of Moderna in a research report on Tuesday, February 18th. Bank of America dropped their target price on Moderna from $41.00 to $34.00 and set an "underperform" rating on the stock in a research report on Tuesday, February 11th. Finally, Leerink Partners cut their target price on Moderna from $31.00 to $27.00 and set an "underweight" rating for the company in a research note on Thursday, January 16th. Four research analysts have rated the stock with a sell rating, sixteen have issued a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus price target of $59.00.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.